AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23111657
Drug: Intravenous peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous peramivir 200 mg once daily (in clinically unstable patients)
Trial: 23111657
Drug: Oral oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oseltamivir 75 mg twice daily (in clinically unstable patients)
Trial: 21501161
Drug: rGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rGH treatment in Group A (n = 8)
Trial: 21501161
Drug: rGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rGH treatment in Group B (n = 5)
Trial: 21501161
Drug: rGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rGH treatment in Groups A (n = 8) and B (n = 5) combined
Trial: 15319705
Drug: Propofol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.2 mg/kg IV bolus)
Trial: 9432343
Drug: Amoxicillin 3
RxNorm normalized name: amoxicillin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3 gm/day and lansoprazole (30-180 mg/day) for 2 weeks
Trial: 8342972
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C and alternating BCG therapy
Trial: 3521480
Drug: Rimantadine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine treatment (200 mg/day for 5 days)
Trial: 27185702
Drug: Gel phantom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel phantom training
Trial: 19001601
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of elemental calcium with 400 IU of vitamin D(3) daily
Trial: 9893199
Drug: Specific IgE
RxNorm normalized name: BSA specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgE antibodies to lentil extract
Trial: 7557504
Drug: Levodopa/Carbidopa administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/Carbidopa administered daily for 3 weeks
Trial: 7557504
Drug: Levodopa/Carbidopa (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/Carbidopa (1 week administration)
Trial: 26036956
Drug: Water extracts
RxNorm normalized name: water birch pollen extract
DrugBank: Betula occidentalis pollen (DB10832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water extracts of Graptopetalum paraguayense (WGP, 4 g day(-1))
Trial: 24434439
Drug: Intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive atorvastatin therapy (80 mg/day)
Trial: 24434439
Drug: Conventional atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional atorvastatin therapy (20 mg/day)
Trial: 26369640
Drug: 0.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 Gy single dose
Trial: 26369640
Drug: 1.0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 Gy single dose
Trial: 19460871
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of oral lorazepam
Trial: 15885165
Drug: Fuhuang Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuhuang Tablets (4 tablets t.i.d. per os)
Trial: 15885165
Drug: Zhining Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhining Tablets (4 tablets t.i.d. per os)
Trial: 12204869
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplementation (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Trial: 6364333
Drug: Tinidazole (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (4 X 500 mg in one single dose)
Trial: 6364333
Drug: Tinidazole (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (4 X 500 mg in one single dose) for non-responders
Trial: 6364333
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg, 4 times daily, for one week)
Trial: 27112810
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CT) with computerized cognitive rehabilitation and right hemifield eye-patching, 15 one-hour sessions
Trial: 27112810
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (ST) with computerized cognitive rehabilitation, 15 one-hour sessions
Trial: 26009783
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP)
Trial: 22211956
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg
Trial: 15839922
Drug: Alfuzosin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 15 mg
Trial: 10333052
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group without antihypertensive treatment (group 3, n = 9)
Trial: 30829116
Drug: Decliners of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decliners of the HPV vaccine
Trial: 26980340
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once daily celecoxib
Trial: 26980340
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg once daily celecoxib
Trial: 26980340
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg three times daily diclofenac
Trial: 25053766
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy Group (MTG)
Trial: 18270762
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with intravenous injection of 5 mg/kg of hematoporphyrin monomethyl ether followed by endoscopic irradiation for 40 min at 150 mW/cm².
Trial: 18270762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no photodynamic therapy).
Trial: 15017018
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment (0.6 mg/kg IV rt-PA, maximum 60 mg over 30 minutes, plus additional rt-PA via microcatheter up to 22 mg over 2 hours)
Trial: 15017018
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment
Trial: 10792277
Drug: Continuous chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous chlorambucil (0.1 mg/kg/d for 7 days, repeated every 6 weeks)
Trial: 10792277
Drug: Intermittent chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent chlorambucil (0.3 mg/kg/d for 7 days, repeated every 6 weeks)
Trial: 3530649
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg orally)
Trial: 20922415
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (250 mg twice a day for 10 days)
Trial: 20922415
Drug: Metronidazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (30 mg/kg twice daily for 10 days)
Trial: 19773535
Drug: Repaglinide administered
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide administered 1 hour after last gemfibrozil dose
Trial: 19773535
Drug: Repaglinide administered
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide administered 24 hours after last gemfibrozil dose
Trial: 19773535
Drug: Repaglinide administered
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide administered 48 hours after last gemfibrozil dose
Trial: 19773535
Drug: Repaglinide administered
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide administered 96 hours after last gemfibrozil dose
Trial: 19773535
Drug: Repaglinide metabolism
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide metabolism inhibition continued up to 48 hours after gemfibrozil administration
Trial: 14659717
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment on normal enamel powder
Trial: 14659717
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment on NaClO-treated enamel powder
Trial: 9549661
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide 30 mg every 8 hours
Trial: 3184782
Drug: 4-mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg nicotine chewing gum
Trial: 28032482
Drug: Edoxaban 15
RxNorm normalized name: edoxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 15 mg, once daily
Trial: 22047812
Drug: Lobeglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 0.5 mg (1 subject placebo)
Trial: 22047812
Drug: Lobeglitazone 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 1, 2, 4, and 8 mg (8 subjects in each group, including 2 receiving placebos)
Trial: 22047812
Drug: Lobeglitazone 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 1, 2, and 4 mg (once daily for 7 days, 8 subjects in each group, including 2 receiving placebos)
Trial: 22047812
Drug: Lobeglitazone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone (various doses)
Trial: 16388508
Drug: First screening
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First screening round with PSA>or=3.0 ng/ml
Trial: 16388508
Drug: Repeat screening
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat screening round with PSA>or=3.0 ng/ml
Trial: 8349825
Drug: lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/d)
Trial: 8349825
Drug: lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin (40 mg b.i.d.) + high cholesterol diet (mean 1,071 mg/d)
Trial: 2872813
Drug: Terazosin (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (5, 10, or 20 mg once daily for four weeks)
Trial: 2872813
Drug: Terazosin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (dose titration until maximum 20 mg)
Trial: 2872813
Drug: Prazosin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (dose titration until maximum 20 mg)
Trial: 26231610
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate therapy for 24 months
Trial: 21145041
Drug: MK-0777 3
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0777 3 mg b.i.d. (n = 18)
Trial: 21145041
Drug: MK-0777 8
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0777 8 mg b.i.d. (n = 21)
Trial: 11077134
Drug: Captopril (6.25-12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25-12.5 mg)
Trial: 11077134
Drug: Losartan (12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (12.5-25 mg)
Trial: 9272365
Drug: DTwP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP vaccine
Trial: 29230548
Drug: cis100 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis100 + RT (conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43)
Trial: 29230548
Drug: cis40 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis40 + ART (accelerated radiotherapy with cisplatin weekly 40 mg/m2)
Trial: 25460855
Drug: Amiodarone discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone discontinuation (group 1)
Trial: 25460855
Drug: No amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No amiodarone discontinuation (group 2)
Trial: 24159603
Drug: ACTH gel
RxNorm normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH gel (16 units)
Trial: 24159603
Drug: ACTH gel
RxNorm normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH gel (32 units)
Trial: 21390311
Drug: Favorable SNP
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favorable SNP variants (CC, AA, TT)
Trial: 21390311
Drug: IP-10 below
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP-10 below 150 pg/mL among genotype 1 infected carriers of favorable alleles
Trial: 8760715
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (100 g)
Trial: 6347995
Drug: Misonidazole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole 2.5 gm/m2 once a week for six weeks (total dose 15 gm/m2) plus radiotherapy (5100 cGy over 6 weeks)
Trial: 6347995
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy (6000 cGy/6-7 weeks) plus BCNU (80 mg/m2 on days 3, 4, 5, repeated q 8 weeks for 2 years)
Trial: 3469101
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg slow-release formulation of diclofenac sodium
Trial: 28895878
Drug: Oat betaglucans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat betaglucans (1.53 g of β‐glucan) administered three times daily before meals for two weeks
Trial: 28895878
Drug: Placebo (Plac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Plac) administered three times daily before meals for two weeks
Trial: 21396122
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving therapy
Trial: 25927191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interventions
Trial: 18478129
Drug: Intravenous moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxifloxacin (400 mg daily) for 5 days starting within 36 hours after stroke onset
Trial: 18478129
Drug: Intravenous moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxifloxacin (400 mg daily) for 5 days
Trial: 18478129
Drug: Intravenous moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxifloxacin (400 mg daily)
Trial: 16509866
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment for 72 weeks (group C)
Trial: 10821722
Drug: Bambuterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol (10 mg oral solution once daily)
Trial: 10821722
Drug: Terbutaline (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.075 mg/kg oral solution three times daily)
Trial: 8994466
Drug: PCA (patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA (patient-controlled intravenous opioid analgesic administration)
Trial: 8398438
Drug: Co-amoxiclav (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (250 mg amoxycillin plus 125 mg clavulanic acid, eight-hourly)
Trial: 8398438
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (250 mg phenoxymethylpenicillin, six-hourly)
Trial: 3510944
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with chlorambucil and cisplatin
Trial: 3510944
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with chlorambucil and cisplatin
Trial: 3510944
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment with cisplatin after initial chlorambucil failure
Trial: 27052296
Drug: Whole-brain radiotherapy
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiotherapy combined with sodium glycididazole at a dose of 700mg/m² intravenous infusion 30 minutes before radiotherapy, three times a week
Trial: 16390366
Drug: 0.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/day omega-3 fatty acids
Trial: 16390366
Drug: 1.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g/day omega-3 fatty acids
Trial: 16390366
Drug: 2.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g/day omega-3 fatty acids
Trial: 10994618
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment (n = 10)
Trial: 4006647
Drug: ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid, 800 mg/day
Trial: 4006647
Drug: ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid, 400 mg/day
Trial: 4006647
Drug: chenodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chenodeoxycholic acid, 750 mg/day
Trial: 4006647
Drug: chenodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chenodeoxycholic acid, 375 mg/day
Trial: 30930022
Drug: GS-4774 (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-4774 (2, 10, or 40 yeast units) with Tenofovir Disoproxil Fumarate (TDF) 300 mg daily
Trial: 7526067
Drug: intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous placebo
Trial: 21877761
Drug: Ipragliflozin (ASP1941),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin (ASP1941), doses ranging from 5-600 mg, administered once daily for 10 days
Trial: 19236490
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive craniopuncture therapy
Trial: 16552540
Drug: Topical Licochalcone
RxNorm normalized name: Licochalcone A
DrugBank: Licochalcone A (DB19281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Licochalcone A (LicA)
Trial: 12940503
Drug: D-cycloserine (0-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (0-500 mg/70 kg, per os)
Trial: 12940503
Drug: D-cycloserine (0-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (0-500 mg/70 kg, per os) combined with naloxone (0.15 mg/70 kg, intramuscularly)
Trial: 12940503
Drug: Naloxone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.15 mg/70 kg, intramuscularly)
Trial: 1549149
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (10 mg/m²)
Trial: 1549149
Drug: Very-low-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very-low-dose methotrexate (5 mg/m²)
Trial: 3983884
Drug: Theophylline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (10 mg/ml)
Trial: 3983884
Drug: Glycine theophyllinate
RxNorm normalized name: Theophylline Sodium Glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine theophyllinate (50 mg/ml)
Trial: 3983884
Drug: Aminophylline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (50 mg/ml)
Trial: 3983884
Drug: Diprophylline (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprophylline (125 mg/ml)
Trial: 3983884
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 micrograms from a metered dose inhaler)
Trial: 27497474
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation (CS) program, twice weekly for eight weeks (EG; n=36)
Trial: 18159575
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine 3 mg + morphine 50 microg
Trial: 18159575
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine 3 mg + morphine 100 microg
Trial: 15513449
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone sodium succinate (1 gram IV/day for 3 days) followed by oral prednisone (1 mg/kg/day for 11 days) with 4‐day taper (20 mg on day 1, 10 mg on days 2 and 4)
Trial: 15513449
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta 1‐a (Avonex 30microg intramuscularly [IM] weekly, or Rebif 22 microg subcutaneously [SQ] weekly)
Trial: 15513449
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone alone, without prior treatment with IV methylprednisolone